(Q34608603)

3 August 2017

title

Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria (English)

1 reference

3 August 2017

Wolfgang Haas

1

1 reference

3 August 2017

Chris M Pillar

2

1 reference

3 August 2017

Gary E Zurenko

3

1 reference

3 August 2017

Jacqueline C Lee

4

1 reference

3 August 2017

Lynne S Brunner

5

1 reference

3 August 2017

Timothy W Morris

6

1 reference

3 August 2017

language of work or name

English

0 references

publication date

8 June 2009

1 reference

Antimicrobial Agents and Chemotherapy

3 August 2017

published in

1 reference

3 August 2017

volume

53

1 reference

3 August 2017

issue

8

1 reference

3 August 2017

page(s)

3552-3560

1 reference

Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study

3 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715578

Bacterial conjunctivitis: a review for internists.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715578

Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715578

Acute bacterial conjunctivitis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715578

Antibiotics versus placebo for acute bacterial conjunctivitis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715578

Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715578

Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715578

Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715578

Update on bacterial conjunctivitis in South Florida.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715578

Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis

26 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19506065

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1128/AAC.00418-09

1 reference

3 August 2017

1 reference

3 August 2017

1 reference